IGF1 and type 2 diabetes mellitus: In addition, exogenous IGF-1 administration has been shown to reduce serum glucose levels [95, 143, 144], not only in healthy individuals [140, 145–147], but also in those with insulin resistance [148, 149], type I [150–152], and T2D [153–155].